Journal Article

Ciprofibrate represses α<sub>2u</sub>-globulin expression in liver and inhibits d-limonene nephrotoxicity

Keith Alvares, V. Subbarao, M.Sambasiva Rao and Janardan K. Reddy

in Carcinogenesis

Volume 17, issue 2, pages 311-316
Published in print February 1996 | ISSN: 0143-3334
Published online February 1996 | e-ISSN: 1460-2180 | DOI:
Ciprofibrate represses α2u-globulin expression in liver and inhibits d-limonene nephrotoxicity

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


Peroxisome proliferators are a class of compounds which induce hepatomegaly and peroxisome proliferation in liver parenchymal cells. One of the earliest known effects of peroxisome proliferators is the rapid transcriptional activation of thegenes responsible for the peroxisomal β-oxidation system in liver. Long term administration of these chemicals to rats and mice results in the development of hepatocellular carcinomas. Here we report that mRNA for α2u-globulin, a rodent male specific protein, is markedly reduced or undetectable by Northern blot analysis of total RNA in thelivers of rats treated with ciprofibrate. This was further confirmed by immunoblot analysis using antibodies against α2u-globulin. Nevertheless, immunohistochemical staining and in situ hybridization showed respectively the presence of a few cells that contained α2u-globulin protein and its mRNA. The α2u-globulin mRNA reappeared in the liver 2 weeks following the cessation of ciprofibrate treatment. Feeding of ciprofibrate for two weeks followed by simultaneous feeding of ciprofibrate and a nephrotoxic chemical d-limonene for 5 weeksrevealed that ciprofibrate prevented the renal accumulation of α2u-globulin and the nephrotoxicity associated with the binding of d-limonene with α2u-globulin.

Journal Article.  0 words. 

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.